A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study to Assess the Efficacy, Safety, and Tolerability of PXT3003 in Charcot-Marie-Tooth Type 1A (CMT1A)
A Study to Test a New Drug (PXT3003-06) in Patients with Charcot-Marie-Tooth Type 1A (CMT1A)
Sponsor: Pharnext
Enrolling: Male and Female Patients
Study Length: 15 Months
Clinic Visits: 8
IRB Number: AAAT5360
Contact: Raisy Fayerman: 212-305-6035 / rf2632@cumc.columbia.edu
Additional Study Information: The main purpose of this study is to investigate how effective PXT3003 is when compared to a placebo, on the disease progression and symptoms of CMT1A. The study also aims to assess the safety and tolerability (whether side effects of a medication can be handled by patients) of PXT3003. We are enrolling male and non-pregnant female subjects, aged 16 to 65 years with a genetically proven diagnosis of CMT1A.
This study is closed
Investigator
Thomas Brannagan, MD
Do You Qualify?
Are you a male or non-pregnant female, aged 16 to 65 years? Yes No
Have you received a genetically-proven diagnosis of CMT1A? Yes No
Have you been on a stable dose of prescribed psychoactive drugs in the past 4 weeks? Yes No
Have you been on a stable dose of prescribed or 'over-the-counter' (OTC) analgesic medications in the past 2 weeks? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder


CAPTCHA
Image CAPTCHA
Enter the characters shown in the image.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Cancel
For more information, please contact:
Raisy Fayerman
rf2632@cumc.columbia.edu
212-305-6035
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE